By exploring the molecular mechanisms underlying liver regeneration, the specific roles of FGF21 and HGFR in tissue repair, and their potential synergistic effects as a chimeric fusion protein, we aim to shed light on its efficacy and translational potential as a therapeutic intervention for NAFLD. The gene discussed is MET; the disease is metabolic dysfunction-associated steatotic liver disease.